Antagonism of IAPs Enhances CAR T-cell Efficacy
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Chimeric antigen receptor (CAR) T-cell therapy has proven successful in the treatment of hematological malignancies, notably acute lymphoblastic leukemia and B-cell lymphoma. However, the efficacy of CAR T cells against solid tumors is poor, likely due to tumor-associated immunosuppression. Here, we demonstrated that antagonizing the “inhibitor of apoptosis proteins” with the clinical smac-mimetic, birinapant, significantly enhanced the antitumor activity of CAR T cells in a tumor necrosis factor (TNF)-dependent manner. Enhanced tumor cell death occurred independently of the perforin-mediated granule exocytosis pathway, underscoring the cytotoxic potential of CAR T-cell–derived TNF. Combining CAR T-cell therapy with birinapant significantly reduced established tumor growth in vivo, where either therapy alone was relatively ineffective. Using patient biopsy-derived tumoroids, we demonstrated the synergistic potential of combining CAR T-cell therapy with smac-mimetics. Taken together, we identified CAR T-cell–derived TNF as a potent antitumor effector, which can be further harnessed by smac-mimetics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ahmed, N., Brawley, V. S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., Liu, E., Dakhova, O., Ashoori, A., Corder, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.0225 · Cited by 1,004
Tumor immune evasion arises through loss of TNF sensitivity
Kearney, C. J., Vervoort, S. J., Hogg, S. J., Ramsbottom, K. M., Freeman, A. J., Lalaoui, N., Pijpers, L., Michie, J., Brown, K. K., Knight, D. A., et al. (2018) · Science Immunology · doi:10.1126/sciimmunol.aar3451 · Cited by 381 · cited 6×
“We have previously uncovered a critical role of the TNF-mediated apoptotic pathway as a mechanism of inducing tumor cell death in the absence of direct T-cell contact (7, 15).”
BackgroundSelf-citationPD-L1 and IAPs co-operate to protect tumors from cytotoxic lymphocyte-derived TNF
Kearney, C. J., Lalaoui, N., Freeman, A. J., Ramsbottom, K. M., Silke, J., & Oliaro, J. (2017) · Cell Death & Differentiation · doi:10.1038/cdd.2017.94 · Cited by 83
Self-citation
Cited by
Gasdermin E–mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome
Liu, Y., Fang, Y., Chen, X., Wang, Z., Liang, X., Zhang, T., Liu, M., Zhou, N., Lv, J., Tang, K., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.aax7969 · Cited by 566
Immunogenic cell death in cancer: targeting necroptosis to induce antitumour immunity
Meier, P., Legrand, A. J., Adam, D., & Silke, J. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00674-x · Cited by 382
Self-citationCAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?
Wagner, J., Wickman, E., DeRenzo, C., & Gottschalk, S. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.015 · Cited by 380
Xiao, X., Huang, S., Chen, S., Wang, Y., Sun, Q., Xu, X., & Li, Y. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02148-6 · Cited by 310
Dufva, O., Koski, J., Maliniemi, P., Ianevski, A., Klievink, J., Leitner, J., Pölönen, P., Hohtari, H., Saeed, K., Hannunen, T., et al. (2020) · Blood · doi:10.1182/blood.2019002121 · Cited by 224
Metadata
- Authors
- Michie, J., Beavis, P. A., Freeman, A. J., Vervoort, S. J., Ramsbottom, K. M., Narasimhan, V., Lelliott, E. J., Lalaoui, N., Ramsay, R. G., Johnstone, R. W., Silke, J., Darcy, P. K., Voskoboinik, I., Kearney, C. J., & Oliaro, J.
- Venue
- Cancer Immunology Research
- Published
- 2019-02-01
- Volume
- 7
- Issue
- 2
- Pages
- 183-192
- ISSN
- 2326-6066 (ISSN-L)
- 2326-6074
- OpenAlex
- W2909163111
- Cited by
- 99
- References
- 3
- FWCI
- 4.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antagonism of IAPs Enhances CAR T-cell Efficacy. https://app.cochat.ai/papers/10.1158/2326-6066.cir-18-0428
- The paper
- Michie, J., Beavis, P. A., Freeman, A. J., Vervoort, S. J., Ramsbottom, K. M., Narasimhan, V., Lelliott, E. J., Lalaoui, N., Ramsay, R. G., Johnstone, R. W., Silke, J., Darcy, P. K., Voskoboinik, I., Kearney, C. J., & Oliaro, J. (2019). Antagonism of IAPs Enhances CAR T-cell Efficacy. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-18-0428
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.